US blow for drugs firm

Shares in AstraZeneca tumbled 6% today after a key drug it has developed in the fight against strokes was provisionally rejected by US regulators.

AstraZeneca was told it needed to provide more data on Exanta amid fears that the blood-thinning drug could cause liver failure in patients over the long term.